Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain from losses […]
Pain Management
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder […]
Ear-puffing device for migraine treatment wins FDA breakthrough designation
A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA. Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up. The device […]
NeuroMetrix revenues rise in Q1
NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]
Abbott launches upgraded digital health app for neurostimulation
Abbott (NYSE:ABT) announced today that it launched an upgraded version of its NeuroSphere myPath digital health app. The Abbott Park, Illinois-based company designed the upgraded app with enhanced functionality to help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. According to a news release, Abbott’s digital […]
Medtronic survey says pandemic has negatively impacted those with chronic back and leg pain
Medtronic (NYSE:MDT) today released data from a survey demonstrating several struggles for those with chronic pain during the COVID-19 pandemic. The survey, commissioned by Medtronic and conducted by public opinion research firm The Harris Poll, found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% […]
Nevro rises on Street-beating Q4 sales
Nevro (NYSE:NVRO) shares ticked up today on fourth-quarter results that beat the consensus revenue forecast. The Redwood City, California-based company posted losses of $30.1 million, or -86¢ per share, on sales of $102.8 million for the three months ended Dec. 31, 2021, for a large bottom-line slide deeper into the red on a sales decline […]
Nevro touts 12-month data for 10 kHz spinal cord stimulation
Nevro (NYSE:NVRO) today reported positive 12-month data from the Senza-NSRBP randomized controlled trial of its implantable neurostimulation device for back pain. Redwood City, California–based Nevro’s data, published in Journal of Neurosurgery: Spine, showed that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients in comparison […]
UnitedHealthcare to cover Abbott’s non-opioid neurostimulation therapy for nerve pain
Abbott (NYSE:ABT) announced today that UnitedHealthcare updated a medical policy that expands access to certain neurostimulation devices. UnitedHealthcare updated its “Implanted Electrical Stimulator for Spinal Cord” policy, increasing patient access to Abbott’s non-opioid dorsal root ganglion (DRG) neurostimulation device for treating chronic pain. The updated policy covers 26 million UnitedHealthcare commercial members and will go […]
NeuroMetrix reports Q4 losses
NeuroMetrix (NSDQ:NURO) today reported fourth-quarter results that included a bottom-line slide. The Woburn, Massachusetts–based neurostimulation technology developer posted losses of $1 million, or 15¢ per share, on sales of $1.8 million for the three months ended Dec. 31, 2021, for a bottom-line dip deeper into the red on sales growth of 0.6%. NeuroMetrix develops the […]
FDA approves Medtronic’s spinal cord stimulation for chronic pain from diabetic neuropathy
Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain. The approval covers the Intellis rechargeable neurostimulator and the Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy. The new indication offers DPN patients access to Medtronic’s spinal cord stimulation (SCS) portfolio of both […]
